The price-to-earnings ratio for Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is above average at 17.19x, Company’s 36-month beta value is 0.08.Analysts have differing opinions on the stock, with 12 analysts rating it as a “buy,” 7 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for REGN is 105.92M, and currently, short sellers hold a 1.98% ratio of that floaft. The average trading volume of REGN on January 24, 2025 was 862.47K shares.
REGN) stock’s latest price update
The stock of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has increased by 2.15 when compared to last closing price of 680.03. Despite this, the company has experienced a -1.25% fall in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-23 that NEW YORK, NY / ACCESS Newswire / January 23, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
REGN’s Market Performance
Regeneron Pharmaceuticals, Inc (REGN) has seen a -1.25% fall in stock performance for the week, with a -1.92% decline in the past month and a -28.28% plunge in the past quarter. The volatility ratio for the week is 2.74%, and the volatility levels for the past 30 days are at 2.61% for REGN. The simple moving average for the past 20 days is -1.70% for REGN’s stock, with a -27.30% simple moving average for the past 200 days.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with UBS repeating the rating for REGN by listing it as a “Neutral.” The predicted price for REGN in the upcoming period, according to UBS is $738 based on the research report published on January 16, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see REGN reach a price target of $565. The rating they have provided for REGN stocks is “Underperform” according to the report published on December 10th, 2024.
Wolfe Research gave a rating of “Outperform” to REGN, setting the target price at $1150 in the report published on November 15th of the previous year.
REGN Trading at -5.89% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.65% of loss for the given period.
Volatility was left at 2.61%, however, over the last 30 days, the volatility rate increased by 2.74%, as shares sank -1.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.75% lower at present.
During the last 5 trading sessions, REGN fell by -1.25%, which changed the moving average for the period of 200-days by -26.31% in comparison to the 20-day moving average, which settled at $706.62. In addition, Regeneron Pharmaceuticals, Inc saw -2.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.84 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.34. The total capital return value is set at 0.12. Equity return is now at value 17.17, with 13.37 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.57. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 63.56.
Currently, EBITDA for the company is 4.69 billion with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 5.47. The receivables turnover for the company is 2.27for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.28.
Conclusion
In a nutshell, Regeneron Pharmaceuticals, Inc (REGN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
